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Abstract
Abstract
Objective — To develop and validate a set of practical prediction tools
that reliably estimate the outcome of subarachnoid haemorrhage from
ruptured intracranial aneurysms (SAH).
Design — Cohort study with logistic regression analysis to combine
predictors and treatment modality.
Setting — Subarachnoid Haemorrhage International Trialists’ (SAHIT)
data repository, including randomised clinical trials, prospective
observational studies, and hospital registries.
Participants — Researchers collaborated to pool datasets of prospective
observational studies, hospital registries, and randomised clinical trials
of SAH from multiple geographical regions to develop and validate clinical
prediction models.
Main outcome measure — Predicted risk of mortality or functional
outcome at three months according to score on the Glasgow outcome
scale.
Results — Clinical prediction models were developed with individual
patient data from 10 936 patients and validated with data from 3355
patients after development of the model. In the validation cohort, a core
model including patient age, premorbid hypertension, and neurological
grade on admission to predict risk of functional outcome had good
discrimination, with an area under the receiver operator characteristics
curve (AUC) of 0.80 (95% confidence interval 0.78 to 0.82). When the
core model was extended to a “neuroimaging model,” with inclusion of
clot volume, aneurysm size, and location, the AUC improved to 0.81
(0.79 to 0.84). A full model that extended the neuroimaging model by
including treatment modality had AUC of 0.81 (0.79 to 0.83).
Discrimination was lower for a similar set of models to predict risk of
mortality (AUC for full model 0.76, 0.69 to 0.82). All models showed
satisfactory calibration in the validation cohort.
Conclusion — The prediction models reliably estimate the outcome of
patients who were managed in various settings for ruptured intracranial
aneurysms that caused subarachnoid haemorrhage. The predictor items
are readily derived at hospital admission. The web based SAHIT
prognostic calculator (http://sahitscore.com) and the related app could
be adjunctive tools to support management of patients.
Introduction
Subarachnoid haemorrhage from a ruptured intracranial
aneurysm (SAH) is a relatively uncommon but severe subtype
of stroke that is associated with a sudden dramatic onset in
otherwise apparently healthy individuals and often results in
poor outcomes. On average, a third of affected individuals do
not survive; at least one in five of those who do survive are
unable to regain functional independence.1 SAH is unlike the
more common ischaemic stroke as it affects younger adults
(median age 55) and therefore results in disproportionately many
years of lost productive life.1 2 Predicting the outcome of this
condition can be challenging given the considerable
heterogeneity in the characteristics of affected individuals and
their clinical course and variability in morphology of the
aneurysm. Reliance on clinical intuition alone might be
insufficient for accurate prognosis of outcome.3 Thus, it is
important that clinicians, affected individuals, and their family
members have reliable evidence based tools that could inform
expectations of outcome and decisions about treatment. This is
important as reliance on clinical judgment alone could lead to
overly pessimistic expectation of outcomes, which potentially
could lead to withholding of treatment that otherwise could be
lifesaving.3
Clinical prediction models statistically combine a set of
characteristics of the patient and disease to estimate the
probability of an outcome. They can be useful decision support
tools, assisting clinicians in the complex choices they make
about patient management and, in turn, facilitating evidence
informed discussions with the patient and family members
around outcome expectations for shared decision making.4
According to some studies, outcome prediction tools can
outperform clinical intuition in patients with stroke.5 Several
prediction models and risk scores have been developed for
patients with SAH, but their uptake into clinical practice is
limited.6 The reasons might be related to the use of suboptimal
study design and analysis in the development of these tools, the
lack of representativeness, the ease of use in clinical setting, or
the absence of evidence of their generalisability in different
settings, as shown in a systematic review.6 Therefore, validated
easy to use prediction tools are urgently needed to support the
management of SAH.
We developed and validated a set of clinical prediction models
to support management after hospital admission of patients with
SAH.
Methods
Study design and data source
We assembled a multidisciplinary team of researchers who
collaborated to establish a repository of datasets of randomised
clinical trials, prospective observational studies, and hospital
registries. We previously reported the purpose, structure, and
content of this database called the subarachnoid haemorrhage
international trialists’ (SAHIT) repository,7 8 which archives the
de-identified patient level data of patients with SAH from
tertiary health institutions from different geographical regions,
including Europe, North America, Oceania, and Asia, and
datasets of randomised controlled trials. The development cohort
included 10 936 patients from seven randomised controlled
trials9-15 and two prospective observational hospital registries.16-18
The randomised controlled trials were the Clazosentan to
Overcome Neurological Ischemia and Infarction occurring after
SAH trial; Intraoperative Hypothermia for Aneurysm Surgery
Trial; Intravenous Magnesium Sulphate for Aneurysmal
Subarachnoid Haemorrhage trial; International Subarachnoid
Aneurysm Trial; the Tirilazad trials; the Magnesium Sulphate
in Aneurysmal Subarachnoid Haemorrhage trials; and the
Heinrich Heine University Concomitant Intraventricular
Fibrinolysis and Low-Frequency Rotation After Severe
Subarachnoid Haemorrhage trial. The prospective registries
were the dataset of subarachnoid treatment of the University of
Washington and the subarachnoid haemorrhage outcomes project
of Columbia University. We excluded the following available
datasets from the analysis: a hospital cohort from the University
of Chicago; the Matrix and Platinum Science trial; the
Neurocognitive Outcome Observational Studies from the
University of Leeds; and another from the University of Durham.
These studies did not record or provide data on clinical severity
at admission or on outcomes (Glasgow outcome scale or
modified Rankin scale). Table A in the appendix presents their
details and specific reasons for the exclusion. The validation
cohort included 3355 patients from seven studies (three
randomised controlled trials and four hospital registries) that
contributed data for archiving in the repository after the
development of the prediction models. The trials were the British
Aneurysm Nimodipine trial,19 the Acute Systemic Erythropoietin
Therapy to Reduce Delayed Ischemic Deficits following SAH,
and the Effects of Acute Treatment with Statins on Cerebral
Autoregulation in patients after SAH trials.20 The hospital series
were from Kurashiki Central Hospital, Japan; St Michael’s
Hospital, Toronto, Canada; University Medical Centre Utrecht
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2018;360:j5745 doi: 10.1136/bmj.j5745 (Published 18 January 2018) Page 2 of 17
RESEARCH
SAH Registry; and the Swiss study on SAH—a nationwide
registry of SAH from Switzerland.21 We excluded two datasets
from the validation analysis: the albumin in subarachnoid
haemorrhage trial and the cerebral aneurysm re-rupture after
treatment study (table A in the appendix for the reasons for the
exclusion). None of the randomised controlled trials found a
significant treatment effect for the studied intervention; this
allowed us to pool data from both treatment and control groups
in our analysis. The exceptions were for the British Aneurysm
Nimodipine trial, as patients who received oral nimodipine had
reduced incidence of cerebral infarction and improved outcome,
and the International Subarachnoid Aneurysm Trial, as outcome
differed in patients who were treated by surgical clipping and
those who were treated by endovascular coiling. We included
treatment modality as a predictor in the models. In all studies,
a very small proportion of patients re-bled and some had the
aneurysm revisited, the exception was the clazosentan study.
Variable selection
In a published systematic review, we identified relevant
predictors of outcome in patients with SAH.6 We searched
PubMed, Embase, and Web of Science databases without
language or time restrictions to retrieve relevant studies. Eligible
studies had a primary endpoint of mortality or functional
outcome assessed with the modified Rankin scale or the
Glasgow outcome scale. The review was conducted according
to PRISMA guidelines. Based on the results of this published
review, we selected the following predictor variables that are
assessable early at hospital admission and are consistently
associated with outcomes for inclusion in the prediction models:
•Age (kept as continuous predictor in the analysis)
•Clinical severity on admission measured by the World
Federation of Neurosurgical Societies (WFNS) scale (five
category ordinal scale)
•Premorbid history of hypertension (yes or no)
•Volume of subarachnoid haemorrhage on computed
tomography on admission (according to the four category
Fisher grade)
•Size and the location of the ruptured aneurysm
•Method of treatment (whether the patient had surgical
clipping, endovascular coiling, or conservative treatment
only).
In the analysis, we categorised aneurysm size as ≤12 mm, 13-24
mm, or ≥25 mm and aneurysm location as anterior cerebral
artery (including ruptured anterior communicating artery
aneurysms), internal carotid artery aneurysms, middle cerebral
artery aneurysms, or posterior circulation aneurysms (including
vertebral and basilar artery aneurysms).
Outcome measure
The outcome measure was score on the Glasgow outcome scale
at three months. On this five category ordinal scale, 1=dead,
2=persistent vegetative state, 3=severe disability, 4=moderate
disability, and 5=good recovery (⇓). The scale was dichotomised
for mortality (1 v 2-5) or for functional outcome (unfavourable
(1, 2, 3) v favourable (4, 5)). We imputed scores at two month
for the International Subarachnoid Aneurysm Trial and scores
at six month for the Washington University registry and the
Erythropoietin trial datasets. For the Kurashiki hospital and
Swiss studies, in which outcome was assessed at 12 months
with the modified Rankin scale (mRS), we imputed this for the
Glasgow outcome scale (GOS) as follows: mRS score 0 and 1
= GOS score 5, mRS score 2 and 3 = GOS score = 4, mRS score
4 = GOS score 3, mRS score 5 = GOS score 2, mRS score of 6
= GOS score 1. Previous studies have used similar techniques
to input outcome measures for prognostic modelling.2-23
Model development
We used frequency tables and box plots to study the distributions
of categorical variables and restricted cubic splines to explore
non-linearity in the effect of age.24 The association between
predictor variables and Glasgow outcome scale was analysed
by fitting proportional odds logistic regression models adjusting
for the fixed effect of study. Prognostic strength was quantified
as odds ratios with 95% confidence intervals. The relative
importance of each predictor in the models was estimated with
partial R2 statistic, which estimates the independent contribution
of the predictor to the variance of the outcome. Using binary
logistic regression analysis, we developed two sets of prediction
models: one set to predict mortality, the other set to predict
functional outcome. Each set consisted of three models in
increasing order of complexity:
•Core model including patient age, WFNS grade on
admission, and a premorbid history of hypertension
•Neuroimaging model consisting of the core model plus
volume of subarachnoid haemorrhage on computed
tomography on admission and size and location of ruptured
aneurysm lumen
•Full model that extended the neuroimaging model to
include treatment modality.
In all, we developed six prediction models and performed a post
hoc sensitivity analysis to examine interaction terms between
predictors using likelihood ratio tests.
Model performance
We evaluated the overall predictive accuracy of the models with
the R2 statistic.25 Model discrimination—the ability of the models
to differentiate between patients who did or did not have a poor
outcome—was evaluated with AUC (area under the receiver
operator characteristics) curves. A perfect model will have an
AUC of 1 whereas a non-informative model will have an AUC
of 0.5. Model calibration—the ability of the models to produce
unbiased estimates of the probability of the outcome—was
evaluated graphically with calibration plots (plots of observed
versus predicted outcomes) and statistically by computing the
following three measures of calibration:
•A goodness of fit test of the model in the development
cohort
•Calibration-in-the-large, which reflects the difference
between the average of observed outcomes and the average
of predicted outcomes. This statistic corresponds to the
intercept of the regression model refitted with the linear
predictors only at validation. A value of 0 indicates perfect
calibration. Values less than or greater than 0 indicate
average under or over-estimation of the outcome,
respectively25
•Recalibration slope, which is the slope of the refitted model.
It represents the average predictor effects. A value of 1
indicates perfect agreement between the strength of the
predictors in the development and validation data. Values
less than or greater than 1 indicate on average stronger or
weaker predictor effects.25
Model validation
The following procedures were used for model validation:
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• Internal validation, which evaluates the stability of a
prediction model to random changes in sample
composition. Internal validation was performed by the
bootstrap resampling technique, in which regression models
were fitted in 500 bootstrap replicates, drawn with
replacement from the development sample. The model was
refitted in each bootstrap replicate and tested on the original
sample to estimate optimism in model performance
• Internal-external validation: involving cross validation by
omission of each constituent study of the development set
in turn. The AUC derived from this procedure for each
study was pooled with a random effects model, and
heterogeneity between studies was assessed with the I2
statistic
•External validation was performed with the validation
datasets.
We also pooled the AUCs from the individual studies of the
validation set using a random effects model, and assessed
heterogeneity between studies with the I2 statistic.
Handling of missing data
Some data were missing for all variables, except for age and
treatment modality. We filled in missing data using the technique
of multiple imputation by chained equations, which samples
imputed values from the posterior predictive distributions of
missing data.26 We assumed data were missing at random.25 The
imputation model was specified on all predictors, outcomes,
and dummy variables for study. We generated 20 datasets for
analysis that were identical with respect to non-missing data
but could vary on imputed values. In all, we imputed 4309 of
the 54 680 values (7.9%) needed for the core model; 9286 of
the 87 488 values (10.6%) needed for the neuroimaging model;
and 9286 of the 98 424 values (9.4%) needed for the full model.
The significance level was set at 5%. All analyses were
performed with the R software (version 2.15.3; R Foundation
for Statistical Computing) using the rms and MICE packages;
and Stata version 13.1 (Statacorp, College Station, TX).
Patient involvement
Patients were not involved in setting the research question or
the study design. The outcome measures were designed to
incorporate functional outcomes of importance to patients such
as asking them how they are functioning with their jobs and/or
family. Patient advocacy groups, including the Brain Aneurysm
Foundation, will be consulted to advice on and facilitate the
research dissemination to their members, including input on
writing the research summaries, utility of the web calculator for
lay users, and mobile application.
Results
Model development
⇓ compares the distribution of variables between the
development and the validation cohorts. ⇓ show the breakdown
by study. The median age was 53 (interquartile range 44-62) in
the development cohort and 55 (46-65) in the validation cohort.
Most patients were women (71% and 64%, respectively). In the
development cohort, 13% (1317) of patients died and 29%
(2971) survived with unfavourable outcome. The proportions
in the validation cohort were 17% (483) and 28% (809),
respectively. Ruptured aneurysms were more often clipped than
coiled in the development cohort; in the validation cohort,
however, they were more often coiled than clipped. We found
the effect of age could be adequately modelled as a linear
function, though a soft inflection point was noted at about age
60. There was no significant correlation between individual
predictor variables. As shown in ⇓, WFNS grade on admission
had the strongest prognostic effect (partial R2=12.0%); followed
by age (R2=1.9%); treatment modality (R2=1.3%); clot burden
on computed tomography (R2=0.65%); premorbid history of
hypertension (R2=0.37%); aneurysm size (R2=0.12%); and
aneurysm location (R2=0.06%). The predictors collectively
explained 23-31% of the variability in outcome.
Internal-external validation
Bootstrap resampling showed negligible model optimism. The
models had internally validated AUCs between 0.77 and 0.83.
There was no significant lack of fit (goodness of fit P≥0.2 in
all models). Cross validated performance was variable across
studies (⇓ and table B in the appendix). The partial R2 values
ranged between 4% and 46%, and the pooled AUC values were
between 0.74 and 0.77. Model performance was better in
hospital registry cohorts than in cohorts from randomised
controlled trials. The best performance was in the Columbia
University cohort (R2=41-46%; AUC 0.83-0.85) and the lowest
performance in the clazosentan trial cohort (R2=4-15%; AUC
0.64-0.72). Outcomes were somewhat poorer than predicted in
hospital registry cohorts and better than predicted in randomised
controlled trial cohorts (table B in the appendix). Nonetheless,
the hospital registry cohorts had calibration-in-the-large values
that were closer to the ideal value of 0 and recalibration slope
values that were closer to the ideal values of 1 compared with
their counterparts from randomised controlled trials, indicating
better calibration in the former than the latter cohort.
Performance indices were slightly better for the models to
predict functional outcome (R2=15-46%; AUC 0.66-0.85) than
the models to predict mortality (R2=5-42%; AUC 0.64-0.85).
Extension of the core models to include neuroimaging
parameters and treatment choices had a modest effect on
performance: the AUC improved on average 0.01 but not
uniformly in the constituent cohorts of the development set (⇓).
External validation
The SAHIT prediction models performed well in the pooled
validation dataset and the different constituent samples (see ⇓;
table C in the appendix). In the pooled dataset, R2 values were
between 22% and 31%. The AUC ranged between 0.76 and
0.81, indicating all models had good discrimination.
Discrimination was better with the models to predict functional
outcome than the models to predict mortality (AUC range
0.80-0.81 v 0.76-0.78). Discrimination improved somewhat
with increasing model complexity (⇓). Overall, predictive
accuracy and discrimination varied significantly across studies
(I2=67%, P=0.016 for full model predicting mortality). Better
performance values were noted in the hospital registry cohorts
than the randomised controlled trial cohorts (⇓, table C in the
appendix). The best R2 and AUC values were obtained in the
Swiss study cohort (R2=31-35%; AUC 0.80-0.82). All models
showed good calibration in the pooled data (⇓). Some
miscalibration was noted, with the models to predict mortality
slightly underestimating observed mortality risk and the models
to predict unfavourable outcome slightly overestimating
observed unfavourable outcome. The confidence intervals were
narrow, however, and generally included the observed risk of
the outcome.
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Sensitivity analysis
Some interaction terms were significant at the 5% level,
including that between age and WFNS grade, age and
hypertension, and aneurysm location and treatment modality.
Inclusion of these interaction terms in the main (“full”) model
did not result in improved performance at apparent validation
(table D in the appendix).
Model presentation
We developed an online prognostic calculator based on the
prediction models’ algorithms that is accessible at http://
sahitscore.com. Also available are applications for handheld
devices. The SAHIT prognostic calculator computes the
probabilities of mortality and functional outcomes at three
months, with the associated error margins, given values of the
predictor items for a patient. Table E in the appendix provides
the intercept and coefficients for the different models to support
independent validation studies.
Discussion
Our prediction models for outcome in patients with subarachnoid
haemorrhage performed robustly in a validation cohort from
different geographical regions, time periods, and settings of
care. The models were well calibrated and had good
discrimination. The externally validated AUC was 0.80-0.81
for the models to predict functional outcome and 0.76-0.78 for
the models to predict mortality. The predictor items are
assessable at hospital admission. The web based calculator could
facilitate the adoption into clinical practice.
Strengths and weaknesses of the study
There are potential limitations to our study. The development
set included more trial cohorts than unselected hospital cohorts,
which could account for the relatively low proportion of patients
who died (13%) or survived with an unfavourable outcome
(29%). These proportions, however, are consistent with other
outcomes reported in the literature.2 The patients were also
enrolled over a wide time period, during which there has been
a trend towards increased adoption of endovascular coiling over
surgical clipping and more aggressive treatment of ruptured
aneurysms, even in elderly patients. Nonetheless, we found the
models were robust in the validation cohort with mostly
unselected hospital patients, who were more recently treated
and in whom ruptured aneurysms were more often coiled than
clipped.
Although the follow-up time period varied somewhat, especially
in the validation cohort, the models performed well in the
different constituent samples, including those with follow-up
at three or six months (see ⇓ and table C in the appendix),
indicating robustness to differences in the duration of follow-up.
The best performance was in the Swiss study cohort with
follow-up at 12 months, which suggests that our prediction
models could also reliably predict long term outcome.
The reliability of the models might be confounded by
measurement errors as aneurysm size and the volume of the
subarachnoid haemorrhage on computed tomography might
have been assessed with different methods of imaging and
measurement techniques across studies. Volume might be
difficult to reliably reproduce with current high resolution cranial
computed tomography. In clinical practice, however, various
institutions use different imaging techniques. Therefore, the use
of different imaging techniques might be a strength rather than
a limitation. Though the predictor variables in the models are
the most prognostic for subarachnoid haemorrhage, they
collectively explained a small proportion of the variability in
outcomes (data on overall predictive accuracy as assessed by
the R2 statistic), suggesting that the outcomes are dependent on
several other factors that were not and could not have been fully
captured in the study.
There is the possibility of updating the models as more reliable
predictors of outcome of subarachnoid haemorrhage are
identified. It should be noted, however, that prediction models
generally have R2 values in the range of those of our study, and,
for purposes of assessing prediction in new patients,
discrimination and calibration are the important indices.23-25
Secondary complications that occur during the clinical course,
especially re-bleeding and delayed cerebral ischaemia, could
potentially impact outcome negatively and hence the accuracy
of our models as the predictions are based on predictor items
that are derived at admission. Nonetheless, the development
and validation cohorts included patients who re-bled and in
whom the aneurysm was recoiled or surgically repaired. Rather
than exclude all patients with missing data from the analysis,
we used data imputation to reduce the impact of data loss. The
proportion of missing data also differed between the
development and validation sets. Multiple imputation is now
widely accepted and increasingly used after theoretical and
empirical evidence that the technique is superior to the
traditional complete case analysis.25 The best scenario would
have been that data were completely available for all patients.
For cogent reasons, we had to exclude some studies that were
available at the development or validation stage, creating the
potential for selection bias. Finally, our study was not population
based, hence the models do not account for the small proportion
of individuals who might have died before hospital admission.
Comparison with previous studies
Several prediction models for outcome of subarachnoid
haemorrhage have been described, though their clinical use is
rare. Some examined the validity of predicting mortality in
hospital with generic risk scores designed for critically ill
patients admitted to the intensive care unit—for example, the
simplified acute physiologic score II.27 28 These risk scores are
not specific for subarachnoid haemorrhage, and their validity
to predict outcomes other than mortality in hospital is unknown.
Most specific prediction models were developed from small
datasets, indicating a lack of power; or they reflect experience
from a single hospital, therefore potentially useful only in the
context of that hospital.6 29 Few, if any, have been validated for
use in clinical practice. The FRESH score was developed from
the Columbia University dataset and is designed to predict
cognitive and quality of life outcomes at one year based on the
Hunt and Hess grade, APACHE-II physiological scores at
admission, age, and whether an aneurysm re-bled within 48
hours of the ictus.29 The score was, however, externally validated
for three month functional outcome according to the modified
Rankin scale in the highly selected clazosentan trial cohort
(AUC 0.77).29
A relatively older prognostic model was developed from 3521
patients who were enrolled between 1980 and 1983 into the
prospective multicentre observational international cooperative
study on the timing of aneurysm surgery.30 This model preceded
the widespread use of nimodipine, early aneurysm repair, and
endovascular coiling. These changes in treatment have improved
outcomes after subarachnoid haemorrhage and potentially could
influence the reliability of the model.
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Some previous studies developed prediction models exclusively
from clinical trial datasets, including those of the cooperative
aneurysm study of intravenous nicardipine after SAH,31 the
tirilazad trials in SAH,32 and the international subarachnoid
aneurysm trial.33 Dijkland and colleagues validated the
international subarachnoid aneurysm trial model for two month
case fatality in an independent cohort of 307 patients from a
single hospital.34 Their study showed that though the model had
good discrimination, it calibrated poorly in the unselected
hospital series. The international subarachnoid aneurysm trial
included only patients at equipoise to be treated with
endovascular coil embolisation or surgical clipping, which could
explain the finding. The homogenous nature of trial cohorts,
excluded patients, and treatment effects of simply being enrolled
in a trial might constrain the utility in unselected hospital
patients. This much is corroborated by the results of the
validation analysis of our study, which showed better
performance in hospital registry cohorts than trial cohorts. In
terms of study power and representativeness, our prediction
models far exceed prior prediction models or risk scores for use
in patients with subarachnoid haemorrhage. In addition, we
present extensive validation data on mortality and functional
outcomes in consecutive hospital patients from different regions.
Predicting functional outcome is probably more meaningful to
current practice as more patients survive the condition now than
in previous years,2 and the discussions around expectations of
outcome might now be dominated by concerns around the
quality of functioning.
Implications for patient education, clinical
practice, and research
Patients with subarachnoid haemorrhage and their relatives need
reliable information about the prognosis of this acutely
devastating condition so they can participate effectively in
shared decision making. This is important as they are less likely
to rely only on the clinician’s intuition in making treatment
decisions.3 The web based prognostic calculator is freely
accessible and could serve as a resource to support patient
education and inform discussions around outcome expectations
and management, including rehabilitation needs.5 For instance,
the SAHIT prognostic calculator could be useful in the
outpatient clinic when doctors counsel patients with unruptured
intracranial aneurysms about the prognosis of aneurysm rupture.
In this regard, it complements other evidence based tools such
as the PHASES score to assess the risk of intracranial aneurysm
rupture.35 Our calculator also could be useful to track the
progress of recovery at three month follow-up visit and beyond
and might be useful at the time of discharge to inform
rehabilitation plans. In the acute care setting, the tool could
facilitate evidence informed discussions with the patient and
family members about outcome expectations for shared decision
making and to facilitate timely referral to centres with the
resources to provide the best outcomes. There is growing
consensus to regionalise management of subarachnoid
haemorrhage, and indeed other types of stroke, as it seems that
patients have better outcomes where there is multidisciplinary
care.36 Many affected patients, however, first present to centres
that might lack the necessary resources to optimally treat
subarachnoid haemorrhage, and they might first be seen by
clinicians with less experience in management. Timely referral
of a patient is critical as it can improve outcome after
subarachnoid haemorrhage.36 Our simple core model including
age, premorbid history of hypertension, and neurological status
on admission is potentially useful in settings where there is a
high possibility of subarachnoid haemorrhage but timely referral
is constrained by factors such as delays in obtaining
confirmatory computed tomography of the head or a lumber
puncture, among others.
This model had discrimination and calibration that are
comparable with those of the extended models, including
neuroimaging findings and treatment modality. We suggest that
once results of computed tomography are available, the
neuroimaging model that incorporates such findings should be
used to refine the prediction. The choice of treatment might
impact the utility of a prediction model of subarachnoid
haemorrhage. The “full” model makes consideration for the
nuances of treatment choice and expectation bias on the models’
predictions. For patients at equipoise, endovascular coil
embolisation is preferred to surgical clip ligation.12 For the many
other patients, choice of treatment depends on multiple factors,
including the treating clinicians’ preference and resource
availability, among others. As not all patients will benefit from
definitive intervention, some clinicians take a cautious approach
sometimes withholding definitive repair for some patients,
particularly elderly patients who remain in poor neurological
condition during hospital admission, who might be judged to
do poorly ultimately or in whom life expectancy is anticipated
to be short. Such treatment choice can be self fulfilling and
should be accounted for to reduce the effect of expectation bias.
Our prediction models could also be useful to develop and
evaluate an alternative model of care that integrates evidence
from a suit of prediction models for outcomes after subarachnoid
haemorrhage and secondary complications such as re-bleeding,
seizure, and delayed cerebral ischaemia to identify those patients
at an early stage who might need more or less aggressive
monitoring after the ruptured aneurysm is secured. Guidelines
could be developed in consultation with stakeholders on how
to put this care model into action to facilitate the step up or step
down of patients between costly high intensive care units and
less expensive areas of the hospital to optimise resource
utilisation without compromising quality of care.37 Finally, the
SAHIT prediction models could be useful for research purposes
and the advance of design and analysis of clinical trials in
subarachnoid haemorrhage. For example, they could provide a
more evidence informed approach to patient selection in trials
of novel treatments.
Conclusion
The SAHIT prediction models were based on patient data from
different regions and settings of care and included 10 936
patients in the development set; they reliably estimated outcome
in 3355 patients in the validation set. By comparison, the most
commonly used outcome prediction model in traumatic brain
injury included 9205 patients in the development set (http://
www.tbi-impact.org). The predictor items in the SAHIT
prediction models are readily available at hospital admission,
and their prognostic value is well recognised. We have
developed an app and a web calculator based on the prediction
algorithms (http://sahitscore.com) to support patient education,
clinical practice, and future research.
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What is already known on this topic
Subarachnoid haemorrhage (SAH) from a
ruptured intracranial aneurysm occurs mostly at
the age when individuals are likely to be at the
peak of their career
The prognosis could be poor and challenging to
predict
Several tools have been reported to aid
prediction of outcome, but available tools have
major weaknesses that potentially limit their
routine use in clinical practice
What this study adds
An easy to use practical prediction tool was
developed with the data from a large
multinational population of patients to predict
mortality and functional outcomes after
subarachnoid haemorrhage
The tool performed satisfactorily in a different
set of patients who were treated at different
regions and settings of care
The SAHIT prognostic calculator could support
clinical practice, aid patient education, and
enhance research
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Tables
Table 1| Distribution of predictor variables in development and validation cohorts for model for prediction of outcome after aneurysmal
subarachnoid haemorrhage. Data shown without imputation
Validation set (n=3355)Development set (n=10 936)Predictors and coding
55 (46-65)53 (44-62)Median (IQR) age (years)
Hypertension:
849 (72)4607 (63)  No
331 (28)2725 (37)  Yes
WFNS grade:
1094 (33)5088 (47)  I (good)
908 (28)2711 (25)  II
314 (9)774 (7)  III
370 (11)1222 (11)  IV
611 (18)1039 (10)  V (poor)
Location:
1026 (39)3469 (38)  Anterior cerebral artery
584 (22)2834 (31)  Internal carotid artery
653 (25)1708 (19)  Middle cerebral artery
352 (14)1033 (12)  Posterior circulation
Aneurysm size (mm):
1777 (92)7328 (79)  ≤12
119 (6)1337 (15)  13-24
27 (1)566 (6)  ≥25
Fisher grade
a
:
79 (4)786 (8)  1 (best)
269 (13)1635 (17)  2
851 (42)5226 (55)  3
817 (41)1909 (20)  4 (worst)
Treatment:
1188 (43)7497 (68)  Clipping
1236 (45)2503 (23)  Coiling
335 (12)936 (9)  None
Outcome on Glasgow outcome scale:
1619 (56)5034 (49)  Good
484 (17)2328 (22)  Moderate
238 (8)1331 (13)  Severe
88 (3)323 (3)  Vegetative
483 (17)1317 (13)  Dead
IQR=interquartile range; WFNS=World Federation of Neurosurgical Societies.
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Table 2| Characteristics of development cohorts used to create outcome prediction model for aneurysmal subarachnoid haemorrhage.
Figures do not include missing data
SHOPD-SATHHU
a
TirilazadMASHISATIMASHIHASTCONS-INo (%)Predictor and coding
15004396035521484214332799841310 936Study population
1996-20121983-932008-111991-972000-111997-20022002-082000-032005-061983-2012Enrolment period
55 (45-64)51 (42-62)60 (48-64)52 (42-62)56 (48-65)52 (44-60)57 (48-68)52 (43-60)51 (44-59)53 (44-62)Median (IQR) age (years)
Hypertension:
747 (52)277 (63)—2334 (67)150 (72)—198 (61)601 (60)300 (69)4607 (63)  No
700 (48)162 (37)—1147 (33)57 (28)—129 (39)397 (40)133 (31)2725 (37)  Yes
WFNS grade:
625 (44)165 (37)—1289 (36)730 (49)1335 (63)95 (29)658 (65)191 (44)5088 (47)  I (good grade)
189 (13)82 (18)4 (7)1045 (29)345 (23)549 (25)83 (25)289 (29)125 (28)2711 (25)  II
40 (2)17 (4)9 (15)417 (12)63 (4)134 (6)31 (9)51 (5)12 (2)774 (7)  III
286 (20)84 (19)21 (35)355 (10)219 (15)74 (3)81 (25)—102 (23)1222 (11)  IV
291 (20)91 (20)26 (43)445 (12)126 (8)20 (1)37 (11)—3 (1)1039 (10)  V (poor grade)
Location:
395 (32)137 (31)20 (33)1256 (36)11 (4)1085 (51)—391 (40)174 (42)3469 (38)  Anterior cerebral artery
412 (33)130 (30)11 (18)1046 (30)111 (40)697 (33)—309 (31)118 (29)2834 (31)  Internal carotid artery
209 (17)88 (20)21 (35)711 (20)95 (34)303 (14)—205 (21)76 (18)1708 (19)  Middle cerebral artery
218 (18)84 (19)8 (14)474 (14)62 (22)58 (3)—83 (8)46 (11)1033 (12)  Posterior circulation
Aneurysm size (mm):
984 (67)207 (47)56 (93)2594 (74)143 (70)2078 (97)—876 (88)390 (96)7328 (79)  ≤12
130 (9)222 (51)4 (7)800 (23)14 (7)63 (3)—94 (10)10 (2)1337 (15)  13-24
350 (24)9 (2)—128 (3)46 (23)2 (0.09)—24 (2)7 (2)566 (6)  ≥25
Fisher grade
b
:
210 (15)15 (16)—338 (9)1 (1)114 (5)2 (1)53 (5)—786 (8)  1
315 (22)47 (11)2 (3)455 (13)22 (11)360 (17)24 (7)342 (34)68 (16)1635 (17)  2
695 (48)182 (42)9 (15)2315 (66)43 (21)902 (42)262 (80)473 (47)345 (80)5226 (55)  3
218 (15)142 (32)49 (82)420 (12)141 (68)753 (35)39 (12)130 (13)17 (4)1909 (20)  4
Treatment:
852 (57)439 (100)36 (60)3209 (90)551 (37)1070 (50)141 (43)998 (100)201 (46)7497 (68)  Clipping
286 (19)—24 (40)-738 (50)1073 (50)150 (46)—232 (54)2503 (23)  Coiling
362 (24)——343 (10)195 (13)—36 (11)——936 (9)  None
Outcome on Glasgow outcome scale:
445 (39)167 (38)26 (48)1975 (57)642 (43)930 (47)126 (39)642 (64)81 (19)5034 (49)  Good
272 (24)127 (29)6 (11)462 (13)441 (30)528 (27)60 (18)213 (21)219 (50)2328 (22)  Moderate
128 (11)39 (9)17 (32)424 (12)105 (7)374 (19)60 (18)81 (8)103 (24)1331 (13)  Severe
21 (2)9 (2)4 (7)59 (2)59 (4)130 (6.7)36 (11)1 (0.1)4 (1)323 (3)  Vegetative
270 (24)96 (22)1 (2)578 (17)234 (16)6 (0.3)45 (14)61 (6)26 (6)1317 (13)  Dead
CONS-I=Clazosentan to overcome
neurological ischemia and infarction
occurring after SAH (CONSCIOUS 1) trials
dataset. In CONS-I aneurysm size was
categorised as <15 mm;16-25 mm; >25
mm; IHAST= Intraoperative Hypothermia
for Aneurysm Surgery Trial;
IMASH=Intravenous Magnesium Sulphate
for Aneurysmal Subarachnoid
Haemorrhage; ISAT=International
Subarachnoid Aneurysm Trial; MASH
(MASH I and II combined)=Magnesium
Sulphate in Aneurysmal Subarachnoid
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Haemorrhage; HHU=Heinrich Heine
University Concomitant Intraventricular
Fibrinolysis and Low-Frequency Rotation
After Severe Subarachnoid Haemorrhage
Trial); D-SAT=Dataset of Subarachnoid
Treatment of the University of Washington;
SHOP=Subarachnoid Haemorrhage
Outcomes project of Columbia University;
IQR=interquartile range; WFNS=World
Federation of Neurosurgical Societies.
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Table 3| Characteristics of validation cohorts used to create outcome prediction model for aneurysmal subarachnoid haemorrhage. Figures
do not include missing data
SWISS-SOSSMHKurashikiUTRECHTEPOBRANTNo (%)Predictor and coding
15821734534331605543355Study population
2009-132012-132006-142008-122004-061985-871985-2014Enrolment period
54 (47-64)56 (50-64)65 (54-75)56 (47-65)55 (46-63)48 (35-56)55 (46-65)Median (IQR) age
(years)
Hypertension:
—91 (53)260 (57)——498 (90)849 (72)  No
—82 (47)193 (43)——56 (10)331 (28)  Yes
WFNS grade:
592 (38)76 (44)145 (32)210 (49)51 (32)20 (4)1094 (33)  I (good grade)
276 (18)22 (13)131 (29)104 (24)48 (30)327 (59)908 (28)  II
103 (7)9 (5)25 (5)16 (4)13 (8)148 (27)314 (9)  III
161 (10)16 (9)62 (13)60 (14)27 (17)44 (8)370 (11)  IV
406 (26)42 (24)90 (20)37 (9)21 (13)15 (3)611 (18)  V (poor grade)
Location:
558 (38)72 (47)152 (34)176 (45)68 (43)—1026 (39)  Anterior cerebral
artery
355 (24)17 (11)72 (16)100 (26)40 (25)—584 (22)  Internal carotid artery
341 (23)22 (15)168 (37)85 (22)37 (23)—653 (25)  Middle cerebral artery
207 (14)41 (27)61 (13)28 (7)15 (9)—352 (14)  Posterior circulation
Aneurysm size (mm):
1220 (91)117 (90)440 (97)———1777 (92)  ≤12
96 (7)10 (8)13 (3)———119 (6)  13-24
24 (2)3 (2)————27 (1)  ≥25
Fisher grade
a
:
51 (4)16 (10)1 (0)—11 (7)—79 (4)  1
134 (10)17 (11)110 (33)—8 (5)—269 (13)  2
614 (45)59 (36)161 (48)—17 (11)—851 (42)  3
560 (41)70 (43)63 (19)—124 (78)—817 (41)  4
Treatment:
592 (38)26 (19)324 (71)214 (49)32 (20)—1188 (43)  Clipping
701 (44)114 (81)104 (23)217 (50)100 (63)—1236 (45)  Coiling
280 (18)—25 (6)———335 (12)  None
Outcome on Glasgow outcome scale:
642 (55)109 (69)206 (46)225 (52)69 (43)368 (66)1619 (56)  Good
190 (16)13 (8)109 (24)101 (23)31 (19)40 (7)484 (17)  Moderate
46 (4)5 (3)59 (13)55 (13)33 (21)40 (7)238 (8)  Severe
19 (2)5 (3)50 (11)3 (1)8 (5)3 (1)88 (3)  Vegetative
257 (22)26 (17)29 (6)49 (11)19 (12)103 (19)483 (17)  Dead
BRANT=British Aneurysm Nimodipine trial; EPO=Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid
hemorrhage and Effects of acute treatment with statins on cerebral autoregulation in patients after aneurysmal subarachnoid hemorrhage trials; Kurashiki=Kurashiki
Central Hospital, Japan; SMH=St. Michael’s Hospital, Toronto, Canada; SWISS-SOS=Swiss study on subarachnoid haemorrhage; IQR=interquartile range;
WFNS=World Federation of Neurosurgical Societies.
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Table 4| Association between predictors and three month outcome after aneurysmal subarachnoid haemorrhage, with odds ratios derived
from proportional odds analysis
Partial
R2 (%)
Odds ratios (95% CI)Outcome (%)Predictor
Full modelNeuroimaging modelCore modelUnivariableUnfavourableMortality
1.91.55 (1.44 to 1.64)1.59 (1.50 to 1.68)1.65 (1.56 to 1.75)1.82 (1.72 to 1.92)——Age (years)
Hypertension:
0.4————1094 (25)544 (12)  No
1.32 (1.18 to 1.47)1.31 (1.17 to 1.46)1.29 (1.16 to 1.44)1.73 (1.57 to 1.90)956 (38)522 (21)  Yes
WFNS grade:
12.0————674 (14)206 (4)  I (good grade)
1.69 (1.53 to 1.87)1.66 (1.51 to 1.84)1.79 (1.62 to 1.97)1.83 (1.66 to 2.01)668 (26)239 (9)  II
3.18 (2.71 to 3.72)3.19 (2.72 to 3.74)3.44 (2.93 to 4.03)3.78 (3.20 to 4.46)325 (44)130 (18)  III
4.73 (4.14 to 5.41)4.81 (4.21 to 5.49)5.35 (4.70 to 6.09)5.93 (5.13 to 6.84)594 (53)293 (26)  IV
9.81 (8.29 to 11.61)10.83 (9.14 to 12.84)12.75 (10.83 to 15.01)13.06 (11.30 to 15.09)683 (71)444 (46)  V (poor grade)
Location:
0.1————916 (28)317 (10)  Anterior cerebral artery
0.96 (0.87 to 1.07)0.98 (0.88 to 1.09)—0.98 (0.88 to 1.08)705 (27)313 (12)  Internal carotid artery
0.86 (0.76 to 0.96)0.83 (0.74 to 0.94)—1.06 (0.95 to 1.18)450 (28)188 (12)  Middle cerebral artery
0.97 (0.84 to 1.13)1.08 (0.94 to 1.24)—1.27 (1.11 to 1.45)339 (34)180 (18)  Posterior circulation
Size:
0.1————1801 (26)628 (9)  ≤12
1.22 (1.08 to 1.37)1.26 (1.12 to 1.41)—1.51 (1.35 to 1.69)465 (36)266 (21)  13-24
1.21 (0.95 to 1.54)1.75 (1.39 to 2.19)—2.34 (1.87 to 2.94)227 (47)174 (36)  ≥25
Fisher grade:
0.7————74 (10)37 (5)  1
1.27 (1.03 to 1.56)1.24 (1.01 to 1.52)—1.22 (1.00 to 1.49)233 (15)79 (5)  2
1.72 (1.41 to 2.09)1.72(1.41 to 2.08)—2.55 (2.11 to 3.09)1649 (33)766 (16)  3
2.00 (1.63 to 2.45)1.97(1.61 to 2.40)—3.11 (2.53 to 3.83)676 (38)236 (13)  4
Treatment:
1.3————1881 (26)712 (10)  Clipping
1.14 (1.03 to 1.26)——1.16 (1.06 to 1.26579 (25)166 (7)  Coiling
2.66 (2.21 to 3.21)——5.09 (4.19 to 6.17)511 (60)439 (52)  None
WFNS=World Federation of Neurosurgical Societies.
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Figures
Scores and definitions for Glasgow outcome scale
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AUC values in leave-one-study-out cross validation (internal-external validation) of model to predict outcome after
subarachnoid haemorrhage with mortality outcome on left and functional outcome on right (weights from random effects
analysis)
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AUC values in pooled validation dataset for model to predict outcome after subarachnoid haemorrhage with mortality
outcome on left and functional outcome on right (weights from random effects analysis)
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Calibration plots in pooled validation dataset for model to predict outcome after subarachnoid haemorrhage
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